Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-human Safety Study of Hypoimmune Pancreatic Islet Transplantation in Adult Subjects With Type 1 Diabetes

Next Previous
X
Search
Trial Profile

First-in-human Safety Study of Hypoimmune Pancreatic Islet Transplantation in Adult Subjects With Type 1 Diabetes

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs UP 421 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; First in man
  • Sponsors Sana Biotechnology

    • Most Recent Events

    • 07 Jan 2025 According to a Sana Biotechnology media release, company announced results of the study at four weeks after cell transplantation demonstrate the survival and function of pancreatic beta cells
    • 07 Jan 2025 Results published in the Sana Biotechnology media release
    • 07 Jan 2025 According to a Sana Biotechnology media release, the company will host a webcast conference call to discuss results of this trial today, January 7, 2025 at 1:30 p.m. PT

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top